CORRECTION OF RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONICKIDNEYDISEASE STAGE I–III
Aim. The aim was to investigate the use of the I1–imidazoline receptor agonist moxonidine as an ‘add–on’ agent and determine its effect on heart rate variability in patients with CKD st. I–III and resistant hypertension. Methods. We investigated the safety and efficacy of moxonidine (200–600 mg)...
Main Author: | O. M. Loboda |
---|---|
Format: | Article |
Language: | English |
Published: |
State Institution «Institute of Nephrology NAMS of Ukraine"
2014-08-01
|
Series: | Український Журнал Нефрології та Діалізу |
Subjects: | |
Online Access: | https://ukrjnd.com.ua/index.php/journal/article/view/36 |
Similar Items
-
Treatment of hypertension in overweight patients
by: V G Kukes, et al.
Published: (2015-09-01) -
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01) -
Hypertension treatment features in perimenopausal women
by: Yu V Zhernakova, et al.
Published: (2014-03-01) -
Clinical and Pharmacological Approaches to the Prescription of Centrally Acting Antihypertensive Drugs for Uncontrolled Arterial Hypertension
by: A. V. Strygin, et al.
Published: (2020-11-01) -
Approaches to the treatment of uncontrolled hypertension. Place of the Physiotens®
by: S. N. Tereshchenko, et al.
Published: (2021-07-01)